Global RNA-Based Therapeutics and Vaccines Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2023

  • receipt Report ID : 150693
  • calendar_today Published On: Apr, 2019
  • file_copy Pages: 117
  • list Pharmaceuticals and Healthcare

RNA-based biopharmaceuticals, which includes therapeutics and vaccines, is a relatively new class of treatment and prophylactic for a number of chronic and rare diseases, including cancer, diabetes, tuberculosis and certaincardiovascular conditions.

Scope of the Report:

This report studies the RNA-Based Therapeutics and Vaccines market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the RNA-Based Therapeutics and Vaccines market by product type and applications/end industries.

RNA-based biopharmaceuticals are a relatively new class of therapies that are demonstrating significant growth and potential for the treatment and prevention of chronic and rare diseases.

The global RNA-Based Therapeutics and Vaccines market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.

The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.

North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of RNA-Based Therapeutics and Vaccines.

Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.

Market Segment by Companies, this report covers

Alnylam Pharmaceuticals

Arbutus Biopharma

Arrowhead Pharmaceuticals

BioNTech

CureVac

Dicerna Pharmaceuticals

Regulus Therapeutics

Marina Biotech

MiRagen Therapeutics

Moderna Therapeutics

Quark Pharmaceuticals

Roche

Sylentis

Market Segment by Regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers

RNA-Based Therapeutics

RNA-Based Vaccines

Market Segment by Applications, can be divided into

Oncology

Immunology

Ophthalmology

Cardiovascular Diseases

Infectious Diseases

Genetic Diseases

Others

Frequently Asked Questions

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

Market is segmented on the basis:

  • By Type
  • By Application
  • By Region
  • By Country
  • By Manufacturer

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

Table of Contents

1 RNA-Based Therapeutics and Vaccines Market Overview

1.1 Product Overview and Scope of RNA-Based Therapeutics and Vaccines

1.2 Classification of RNA-Based Therapeutics and Vaccines by Types

1.2.1 Global RNA-Based Therapeutics and Vaccines Revenue Comparison by Types (2017-2023)

1.2.2 Global RNA-Based Therapeutics and Vaccines Revenue Market Share by Types in 2017

1.2.3 RNA-Based Therapeutics

1.2.4 RNA-Based Vaccines

1.3 Global RNA-Based Therapeutics and Vaccines Market by Application

1.3.1 Global RNA-Based Therapeutics and Vaccines Market Size and Market Share Comparison by Applications (2013-2023)

1.3.2 Oncology

1.3.3 Immunology

1.3.4 Ophthalmology

1.3.5 Cardiovascular Diseases

1.3.6 Infectious Diseases

1.3.7 Genetic Diseases

1.3.8 Others

1.4 Global RNA-Based Therapeutics and Vaccines Market by Regions

1.4.1 Global RNA-Based Therapeutics and Vaccines Market Size (Million USD) Comparison by Regions (2013-2023)

1.4.1 North America (USA, Canada and Mexico) RNA-Based Therapeutics and Vaccines Status and Prospect (2013-2023)

1.4.2 Europe (Germany, France, UK, Russia and Italy) RNA-Based Therapeutics and Vaccines Status and Prospect (2013-2023)

1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) RNA-Based Therapeutics and Vaccines Status and Prospect (2013-2023)

1.4.4 South America (Brazil, Argentina, Colombia) RNA-Based Therapeutics and Vaccines Status and Prospect (2013-2023)

1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) RNA-Based Therapeutics and Vaccines Status and Prospect (2013-2023)

1.5 Global Market Size of RNA-Based Therapeutics and Vaccines (2013-2023)

2 Manufacturers Profiles

2.1 Alnylam Pharmaceuticals

2.1.1 Business Overview

2.1.2 RNA-Based Therapeutics and Vaccines Type and Applications

2.1.2.1 Product A

2.1.2.2 Product B

2.1.3 Alnylam Pharmaceuticals RNA-Based Therapeutics and Vaccines Revenue, Gross Margin and Market Share (2016-2017)

2.2 Arbutus Biopharma

2.2.1 Business Overview

2.2.2 RNA-Based Therapeutics and Vaccines Type and Applications

2.2.2.1 Product A

2.2.2.2 Product B

2.2.3 Arbutus Biopharma RNA-Based Therapeutics and Vaccines Revenue, Gross Margin and Market Share (2016-2017)

2.3 Arrowhead Pharmaceuticals

2.3.1 Business Overview

2.3.2 RNA-Based Therapeutics and Vaccines Type and Applications

2.3.2.1 Product A

2.3.2.2 Product B

2.3.3 Arrowhead Pharmaceuticals RNA-Based Therapeutics and Vaccines Revenue, Gross Margin and Market Share (2016-2017)

2.4 BioNTech

2.4.1 Business Overview

2.4.2 RNA-Based Therapeutics and Vaccines Type and Applications

2.4.2.1 Product A

2.4.2.2 Product B

2.4.3 BioNTech RNA-Based Therapeutics and Vaccines Revenue, Gross Margin and Market Share (2016-2017)

2.5 CureVac

2.5.1 Business Overview

2.5.2 RNA-Based Therapeutics and Vaccines Type and Applications

2.5.2.1 Product A

2.5.2.2 Product B

2.5.3 CureVac RNA-Based Therapeutics and Vaccines Revenue, Gross Margin and Market Share (2016-2017)

2.6 Dicerna Pharmaceuticals

2.6.1 Business Overview

2.6.2 RNA-Based Therapeutics and Vaccines Type and Applications

2.6.2.1 Product A

2.6.2.2 Product B

2.6.3 Dicerna Pharmaceuticals RNA-Based Therapeutics and Vaccines Revenue, Gross Margin and Market Share (2016-2017)

2.7 Regulus Therapeutics

2.7.1 Business Overview

2.7.2 RNA-Based Therapeutics and Vaccines Type and Applications

2.7.2.1 Product A

2.7.2.2 Product B

2.7.3 Regulus Therapeutics RNA-Based Therapeutics and Vaccines Revenue, Gross Margin and Market Share (2016-2017)

2.8 Marina Biotech

2.8.1 Business Overview

2.8.2 RNA-Based Therapeutics and Vaccines Type and Applications

2.8.2.1 Product A

2.8.2.2 Product B

2.8.3 Marina Biotech RNA-Based Therapeutics and Vaccines Revenue, Gross Margin and Market Share (2016-2017)

2.9 MiRagen Therapeutics

2.9.1 Business Overview

2.9.2 RNA-Based Therapeutics and Vaccines Type and Applications

2.9.2.1 Product A

2.9.2.2 Product B

2.9.3 MiRagen Therapeutics RNA-Based Therapeutics and Vaccines Revenue, Gross Margin and Market Share (2016-2017)

2.10 Moderna Therapeutics

2.10.1 Business Overview

2.10.2 RNA-Based Therapeutics and Vaccines Type and Applications

2.10.2.1 Product A

2.10.2.2 Product B

2.10.3 Moderna Therapeutics RNA-Based Therapeutics and Vaccines Revenue, Gross Margin and Market Share (2016-2017)

2.11 Quark Pharmaceuticals

2.11.1 Business Overview

2.11.2 RNA-Based Therapeutics and Vaccines Type and Applications

2.11.2.1 Product A

2.11.2.2 Product B

2.11.3 Quark Pharmaceuticals RNA-Based Therapeutics and Vaccines Revenue, Gross Margin and Market Share (2016-2017)

2.12 Roche

2.12.1 Business Overview

2.12.2 RNA-Based Therapeutics and Vaccines Type and Applications

2.12.2.1 Product A

2.12.2.2 Product B

2.12.3 Roche RNA-Based Therapeutics and Vaccines Revenue, Gross Margin and Market Share (2016-2017)

2.13 Sylentis

2.13.1 Business Overview

2.13.2 RNA-Based Therapeutics and Vaccines Type and Applications

2.13.2.1 Product A

2.13.2.2 Product B

2.13.3 Sylentis RNA-Based Therapeutics and Vaccines Revenue, Gross Margin and Market Share (2016-2017)

3 Global RNA-Based Therapeutics and Vaccines Market Competition, by Players

3.1 Global RNA-Based Therapeutics and Vaccines Revenue and Share by Players (2013-2018)

3.2 Market Concentration Rate

3.2.1 Top 5 RNA-Based Therapeutics and Vaccines Players Market Share

3.2.2 Top 10 RNA-Based Therapeutics and Vaccines Players Market Share

3.3 Market Competition Trend

4 Global RNA-Based Therapeutics and Vaccines Market Size by Regions

4.1 Global RNA-Based Therapeutics and Vaccines Revenue and Market Share by Regions

4.2 North America RNA-Based Therapeutics and Vaccines Revenue and Growth Rate (2013-2018)

4.3 Europe RNA-Based Therapeutics and Vaccines Revenue and Growth Rate (2013-2018)

4.4 Asia-Pacific RNA-Based Therapeutics and Vaccines Revenue and Growth Rate (2013-2018)

4.5 South America RNA-Based Therapeutics and Vaccines Revenue and Growth Rate (2013-2018)

4.6 Middle East and Africa RNA-Based Therapeutics and Vaccines Revenue and Growth Rate (2013-2018)

5 North America RNA-Based Therapeutics and Vaccines Revenue by Countries

5.1 North America RNA-Based Therapeutics and Vaccines Revenue by Countries (2013-2018)

5.2 USA RNA-Based Therapeutics and Vaccines Revenue and Growth Rate (2013-2018)

5.3 Canada RNA-Based Therapeutics and Vaccines Revenue and Growth Rate (2013-2018)

5.4 Mexico RNA-Based Therapeutics and Vaccines Revenue and Growth Rate (2013-2018)

6 Europe RNA-Based Therapeutics and Vaccines Revenue by Countries

6.1 Europe RNA-Based Therapeutics and Vaccines Revenue by Countries (2013-2018)

6.2 Germany RNA-Based Therapeutics and Vaccines Revenue and Growth Rate (2013-2018)

6.3 UK RNA-Based Therapeutics and Vaccines Revenue and Growth Rate (2013-2018)

6.4 France RNA-Based Therapeutics and Vaccines Revenue and Growth Rate (2013-2018)

6.5 Russia RNA-Based Therapeutics and Vaccines Revenue and Growth Rate (2013-2018)

6.6 Italy RNA-Based Therapeutics and Vaccines Revenue and Growth Rate (2013-2018)

7 Asia-Pacific RNA-Based Therapeutics and Vaccines Revenue by Countries

7.1 Asia-Pacific RNA-Based Therapeutics and Vaccines Revenue by Countries (2013-2018)

7.2 China RNA-Based Therapeutics and Vaccines Revenue and Growth Rate (2013-2018)

7.3 Japan RNA-Based Therapeutics and Vaccines Revenue and Growth Rate (2013-2018)

7.4 Korea RNA-Based Therapeutics and Vaccines Revenue and Growth Rate (2013-2018)

7.5 India RNA-Based Therapeutics and Vaccines Revenue and Growth Rate (2013-2018)

7.6 Southeast Asia RNA-Based Therapeutics and Vaccines Revenue and Growth Rate (2013-2018)

8 South America RNA-Based Therapeutics and Vaccines Revenue by Countries

8.1 South America RNA-Based Therapeutics and Vaccines Revenue by Countries (2013-2018)

8.2 Brazil RNA-Based Therapeutics and Vaccines Revenue and Growth Rate (2013-2018)

8.3 Argentina RNA-Based Therapeutics and Vaccines Revenue and Growth Rate (2013-2018)

8.4 Colombia RNA-Based Therapeutics and Vaccines Revenue and Growth Rate (2013-2018)

9 Middle East and Africa Revenue RNA-Based Therapeutics and Vaccines by Countries

9.1 Middle East and Africa RNA-Based Therapeutics and Vaccines Revenue by Countries (2013-2018)

9.2 Saudi Arabia RNA-Based Therapeutics and Vaccines Revenue and Growth Rate (2013-2018)

9.3 UAE RNA-Based Therapeutics and Vaccines Revenue and Growth Rate (2013-2018)

9.4 Egypt RNA-Based Therapeutics and Vaccines Revenue and Growth Rate (2013-2018)

9.5 Nigeria RNA-Based Therapeutics and Vaccines Revenue and Growth Rate (2013-2018)

9.6 South Africa RNA-Based Therapeutics and Vaccines Revenue and Growth Rate (2013-2018)

10 Global RNA-Based Therapeutics and Vaccines Market Segment by Type

10.1 Global RNA-Based Therapeutics and Vaccines Revenue and Market Share by Type (2013-2018)

10.2 Global RNA-Based Therapeutics and Vaccines Market Forecast by Type (2018-2023)

10.3 RNA-Based Therapeutics Revenue Growth Rate (2013-2023)

10.4 RNA-Based Vaccines Revenue Growth Rate (2013-2023)

11 Global RNA-Based Therapeutics and Vaccines Market Segment by Application

11.1 Global RNA-Based Therapeutics and Vaccines Revenue Market Share by Application (2013-2018)

11.2 RNA-Based Therapeutics and Vaccines Market Forecast by Application (2018-2023)

11.3 Oncology Revenue Growth (2013-2018)

11.4 Immunology Revenue Growth (2013-2018)

11.5 Ophthalmology Revenue Growth (2013-2018)

11.6 Cardiovascular Diseases Revenue Growth (2013-2018)

11.7 Infectious Diseases Revenue Growth (2013-2018)

11.8 Genetic Diseases Revenue Growth (2013-2018)

11.9 Others Revenue Growth (2013-2018)

12 Global RNA-Based Therapeutics and Vaccines Market Size Forecast (2018-2023)

12.1 Global RNA-Based Therapeutics and Vaccines Market Size Forecast (2018-2023)

12.2 Global RNA-Based Therapeutics and Vaccines Market Forecast by Regions (2018-2023)

12.3 North America RNA-Based Therapeutics and Vaccines Revenue Market Forecast (2018-2023)

12.4 Europe RNA-Based Therapeutics and Vaccines Revenue Market Forecast (2018-2023)

12.5 Asia-Pacific RNA-Based Therapeutics and Vaccines Revenue Market Forecast (2018-2023)

12.6 South America RNA-Based Therapeutics and Vaccines Revenue Market Forecast (2018-2023)

12.7 Middle East and Africa RNA-Based Therapeutics and Vaccines Revenue Market Forecast (2018-2023)

13 Research Findings and Conclusion

14 Appendix

14.1 Methodology

14.2 Data Source

List of Tables and Figures

Figure RNA-Based Therapeutics and Vaccines Picture

Table Product Specifications of RNA-Based Therapeutics and Vaccines

Table Global RNA-Based Therapeutics and Vaccines and

Please fill the form below, to recieve the report sample


+1